期刊文献+

吡格列酮对正常MC3T3-E1成骨细胞增殖、凋亡以及功能蛋白表达的影响 被引量:3

The effects of pioglitazone on proliferation,apoptosis and expressions of functional proteins in the osteoblastic cell MC3T3-E1
下载PDF
导出
摘要 目的探讨不同浓度吡格列酮(PIO)对正常糖浓度培养下MC3T3-E1小鼠早期成骨细胞增殖、凋亡及功能蛋白分泌表达的影响。方法体外培养MC3T3-E1细胞,分为正常对照组、不同浓度PIO干预组(5μmol/L、10μmol/L、20μmol/L、40μmol/L),分别干预24、48 h。CCK-8检测细胞增殖,流式细胞仪检测细胞凋亡率,RIA法和ELISA法分别检测相关功能蛋白骨钙素(OCN)、碱性磷酸酶(ALP),RT-PCR检测过氧化物酶体增殖物激活受体γ(PPARγ)、成骨因子runt相关基因2(Runx2)及骨形成蛋白-2(BMP-2)mRNA表达水平。结果 (1)与对照组比较,MC3T3-E1细胞增殖能力在5μmol/L PIO干预组增加显著(P<0.05)、在PIO大于5μmol/L~10μmol/L干预组则降低(P<0.05)。干预时间由24 h延长至48 h,各组细胞增殖能力呈不同程度增加,但在20、40μmol/L PIO干预的两组增加无统计学差别。(2)对照组及各PIO浓度干预干预24 h,细胞凋亡率分别为:1.97%、0.43%、13.0%、48.30%、81.00%;(3)随着PIO浓度从0~40μmol/L范围内的增加,MC3T3-E1细胞的PPARγmRNA表达水平呈增加趋势(P<0.05);Runx2 mRNA表达量在5μmol/L PIO浓度组时较对照组增加,在剂量较高时(PIO≥10μmol/L)随浓度升高表达下降。(4)细胞功能蛋白ALP、OCN的分泌及BMP-2的表达在5μmol/L PIO浓度组时最高,PIO≥10μmol/L时,上述蛋白量逐渐下降(P<0.05);随干预时间从24~48 h延长,各PIO浓度干预组ALP以及BMP-2量增加(P<0.05),而OCN无显著改变(P>0.05)。结论 PIO对正常糖浓度培养的MC3T3-E1细胞具有双向作用:低浓度促进细胞增殖,高浓度则促进凋亡。PPARγ适当激活可促使成骨细胞通过Runx2增加功能蛋白的合成;过度激活,则表现出细胞毒性。 Objective To investigate the effects of pioglitazone (PIO) on proliferation, apoptosis and expressions of functional proteins in mouse preosteoblastic cells MC3T3-E1 exposed to normal glucose concentration. Methods MC3T3-EI cells were cultured and divided into control group, PIO administration group with different PIO concentrations (5, 10, 20 and 40μmol/L, respectively) and were exposed for 24 or 48 hours. Cell proliferation was tested with CCK-8. Cell apoptosis was detected using quantitative flow cytometry. The secretions of osteocalcin (OCN) and alkaline phosphatase (ALP) were measured using RIA or ELISA, respectively. The mRNA expressions of peroxisome proliferator-activated receptor gamma (PPARγ) , osteogenic factor runt related gene 2 (Runx2) , and bone morphogenetic protein-2 (BMP-2) was detected using semi-quantitative RT-PCR. Results (1) Compared to the control group, cell proliferation was promoted in PIO 5 μmol/L group (P 〈 0.05 ). In cultures administered with PIO concentration higher than 5-10μmol/L, cell proliferation was decreased significantly compared to that in control group (P 〈 0. 05). Extending the interfering time from 24 h to 48 h, cell proliferation in each group increased in a certain extent; however the increase was not statistically significant in 20 and 40 μmol/L PIO groups. (2) In cultures of control and PIO groups exposed for 24 h, the apoptotic rates were 1.97% , 0. 43% , 13.0% , 48.30% , and 81.00% , respectively. (3) In cultures with PIO concentration from 0 to 40 μmol/L, PPART mRNA expression levels of the cell showed a dose-dependent increase (P 〈 0. 05 ). Runx2 mRNA expression increased in PIO 5μmol/L group, but it decreased in groups with PIO doses higher than 10 μmol/L. (4) The secretions of ALP, OCN, and the expression of BMP-2 were the highest in PIO 5 μmol/L group. Those were decreased dose-dependently when PIO concentrations were more than 10 μmol/L (P 〈 0. 05 ). Expressions of ALP and BMP-2 in
出处 《中国骨质疏松杂志》 CAS CSCD 2011年第2期96-101,共6页 Chinese Journal of Osteoporosis
基金 福建省自然科学基金资助项目(2009J01135)
关键词 吡格列酮 过氧化物酶体增殖物激活受体叮 成骨因子runt相关基因 骨钙素 骨形成蛋白-2 Pioglitazone Peroxisome proliferator-activated receptor gamma Osteogenic factor runt related gene2 Osteocalcin Bone morphogenetic protein-2
  • 相关文献

参考文献14

  • 1Patel CB, Lemos JA, Wyne KL, et al. Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism. Diabetes Vasc Dis, 2006, 3: 65-71. 被引量:1
  • 2Eguchi K, Tomizawa H, Ishikawa J, et al. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Hypertens Res, 2007, 30: 23-30. 被引量:1
  • 3Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med, 2006, 355 : 2427-2443. 被引量:1
  • 4Rzonca SO, Suva LJ, Gaddy D, et al. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology, 2004, 145: 401-406. 被引量:1
  • 5Soroceanu MA, Miao D, Bai XY, et al. Rosiglitazone impacts negatively on bone by promoting osteoblast/ostcocyte apoptosis. Endocrinol, 2004, 183 : 203-216. 被引量:1
  • 6Lazarenko OP, Rzonca SO, Suva LJ, et al. Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone, 2006, 38: 74-99. 被引量:1
  • 7Jackson SM, Demer LL. Peroxisome-proliferator activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett, 2000, 471 : 119-124. 被引量:1
  • 8Li M, Pan LC, Simmons HA, et al. Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. Bone, 2006, 39 : 796-806. 被引量:1
  • 9Jung JY, Yoo CI, Kim HT, et al. Role of mitogen-activated protein kinase (MAPK) in troglitazone-induced osteoblastic cell death. Toxicology, 2007, 234: 73-82. 被引量:1
  • 10Yasuda E, Tokuda H, Ishisaki A, et al. PPAR-gamma ligands up-regulate basic fibroblast growth factor-induced VEGF release through amplifying SAPK/JNK activation in osteoblasts. Biochem Biophys Res Commun, 2005, 328: 137-43. 被引量:1

同被引文献5

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部